Suven NCEs receive patents in Australia, New Zealand
The issued patents cover the class of selective 5-HT compounds of Suven that are being developed to treat cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.